Annual report pursuant to Section 13 and 15(d)

Research and Development Agreements - Schedule of Deferred Revenue, Other Liabilities for Co-share Payments and Accounts Receivable Balances from the Research and Development Agreements (Detail)

v3.20.4
Research and Development Agreements - Schedule of Deferred Revenue, Other Liabilities for Co-share Payments and Accounts Receivable Balances from the Research and Development Agreements (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Jan. 01, 2019
Assets      
Accounts receivable, related party $ 234 $ 408  
Liabilities      
Other current liabilities 2,211 2,501  
Other liabilities 1,490 1,366  
Total liabilities 80,537 71,174 $ 4,705
Takeda Pharmaceuticals Inc      
Assets      
Accounts receivable, related party 234 408  
Liabilities      
Other current liabilities 5,614 0  
Deferred revenue, current 789 8,780  
Deferred revenue, non-current 3,106 441  
Other liabilities 6,711 0  
Total liabilities $ 16,220 $ 9,221